Reported Earlier, Edwards Lifesciences RHEIA Trial Discloses TAVI Outcomes for Women With SAPIEN 3 Valves
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences announced positive one-year results from the RHEIA Trial, showing superior outcomes for women receiving TAVI with SAPIEN 3 valves compared to surgical aortic valve replacement.
September 03, 2024 | 7:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences' RHEIA Trial results show superior outcomes for women receiving TAVI with SAPIEN 3 valves, potentially boosting the company's market position and stock price.
The RHEIA Trial results highlight the effectiveness of Edwards Lifesciences' SAPIEN 3 valves in women, which could lead to increased adoption and sales. This positive clinical outcome is likely to enhance investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100